- Exchange: Xetra
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Morphosys AG (MOR)
| Open: | 35.830 | Day's Range: | 35.200 - 36.100 | Volume: | 37,245 |
|---|---|---|---|---|---|
| Previous Close: | 35.645 | 52wk Range: | 16.030 - 36.460 | 1-Yr Rtn: | +100.17% |
Key Statistics for MOR
| Current P/E Ratio (ttm) | 185.7895 |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. DAX | 11.8855 |
| Earnings Per Share (EUR) (ttm) | 0.1900 |
| Est. EPS (EUR) (12/2013) | -0.5060 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 824.55 |
| Shares Outstanding (M) | 23.36 |
| 30 Day Average Volume | 85,977 |
| Price/Book (mrq) | 3.8753 |
| Price/Sale (ttm) | 12.3934 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for MOR
Company Profile & Key Executives for MOR
MorphoSys AG is a biotechnology company. The Company uses proprietary technology to develop human antibodies tailored to treat specific diseases. MorphoSys is developing medicines to treat cancer and inflammation.
| Simon E MoroneyChairman-Mgmt Board/CEO | Jens HolsteinCFO/Member-Mgmt Board |
| Marlies SprollChief Scientific Officer | Arndt SchotteliusChief Development Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
MOR News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page